洛铂、白介素-2、凝血酶、胸腔灌注治疗恶性胸腔积液的临床观察

Clinical observation of lobaplatin combined with IL-2 and thrombin in the treatment of malignant pleural effusion

目的观察洛铂联合白介素-2(IL-2)及凝血酶胸腔灌注治疗恶性胸腔积液的临床疗效。方法将60例NSCLC恶性胸腔积液患者随机分为两组,对照组及观察组各30例,所有患者均采用胸腔穿刺术置入中心静脉导管引流胸腔积液,待排尽胸腔积液后,对照组给予胸腔灌注洛铂,观察组在对照组的基础上联合IL-2和凝血酶胸腔灌注,比较两组患者的临床疗效、毒副反应及生活质量的改善情况。结果两组患者治疗后,观察组患者的生活质量KPS评分及胸水控制的总有效率均明显高于对照组(P<0.05),且毒副反应明显少于对照组(P<0.05)。结论洛铂联合IL-2及凝血酶胸腔灌治疗NSCLC恶性胸腔积液疗效显著、副反应少,值得临床推广。

Objective To observe the clinical effect of lobaplatin combined with IL-2 and thrombin in the treatment of malignant pleural effusion. Methods 60 NSCLC patients with malignant pleural effusion were randomly divided into the control group and the trial group,30 cases in each group. All patients were treated with thoracentesis and inserted central venous catheter to drain pleural effusion. After exhaustion of pleural effusion,the control group was treated with lobaplatin by pleural perfusion,and the trial group was treated with IL-2 and thrombin on the base of the control group. The treatment,side effect and quality of life were compared. Results The improvement of KPS score of living quality and controlling pleural effusion was more pronounced in the trial group than in the control group（ P〈0.05）,and the side effect was significant lower in the trial group than the control group（ P〈0.05）. Conclusion Lobaplatin combined with IL-2 and thrombin pleural perfusion has significant curative effect and less side effect in the treatment of NSCLC patients with malignant pleural effusion.